Intensity Therapeutics Resumes Enrollment in Phase 3 Soft Tissue Sarcoma Study and Restarts Patient Treatment in Phase 2 Breast Cancer Study

Intensity Therapeutics announced the resumption of enrollment in a limited number of U.S. sites for its Phase 3 INVINCIBLE-3 Study for soft tissue sarcoma and the restart of patient treatment in its presurgical triple-negative breast cancer Phase 2 INVINCIBLE-4 Study. This follows an FDA-reviewed amended protocol for the Phase 3 study.